Zacks Research Expects Reduced Earnings for Globus Medical

by · The Cerbat Gem

Globus Medical, Inc. (NYSE:GMED – Free Report) – Zacks Research cut their Q1 2025 EPS estimates for Globus Medical in a research note issued to investors on Thursday, March 13th. Zacks Research analyst R. Department now expects that the medical device company will post earnings of $0.73 per share for the quarter, down from their previous forecast of $0.79. The consensus estimate for Globus Medical’s current full-year earnings is $3.44 per share. Zacks Research also issued estimates for Globus Medical’s Q3 2025 earnings at $0.87 EPS, Q4 2025 earnings at $0.97 EPS, Q1 2026 earnings at $0.87 EPS, Q2 2026 earnings at $0.92 EPS, Q3 2026 earnings at $0.99 EPS, Q4 2026 earnings at $1.14 EPS and FY2027 earnings at $4.49 EPS.

Several other brokerages also recently issued reports on GMED. Canaccord Genuity Group boosted their price target on shares of Globus Medical from $92.00 to $101.00 and gave the company a “buy” rating in a report on Friday, January 10th. Needham & Company LLC reaffirmed a “hold” rating on shares of Globus Medical in a report on Tuesday. Roth Mkm upped their price objective on shares of Globus Medical from $100.00 to $115.00 and gave the stock a “buy” rating in a report on Tuesday, December 17th. Barclays upped their price objective on shares of Globus Medical from $100.00 to $103.00 and gave the stock an “overweight” rating in a report on Monday, February 24th. Finally, Bank of America raised shares of Globus Medical from an “underperform” rating to a “neutral” rating and upped their price objective for the stock from $80.00 to $97.00 in a report on Thursday, January 9th. Three investment analysts have rated the stock with a hold rating and ten have assigned a buy rating to the company. According to data from MarketBeat.com, Globus Medical has a consensus rating of “Moderate Buy” and an average target price of $97.09.

Check Out Our Latest Research Report on Globus Medical

Globus Medical Stock Performance

Shares of GMED opened at $71.63 on Monday. Globus Medical has a 1 year low of $49.33 and a 1 year high of $94.93. The company has a market cap of $9.85 billion, a price-to-earnings ratio of 95.50, a price-to-earnings-growth ratio of 1.61 and a beta of 1.19. The firm has a fifty day moving average of $84.39 and a 200-day moving average of $79.79.

Globus Medical (NYSE:GMED – Get Free Report) last announced its quarterly earnings results on Thursday, February 20th. The medical device company reported $0.84 earnings per share (EPS) for the quarter, beating the consensus estimate of $0.74 by $0.10. Globus Medical had a net margin of 4.09% and a return on equity of 10.83%. The company had revenue of $657.29 million during the quarter, compared to the consensus estimate of $646.19 million.

Institutional Investors Weigh In On Globus Medical

Several hedge funds and other institutional investors have recently modified their holdings of GMED. Crossmark Global Holdings Inc. boosted its stake in Globus Medical by 6.0% during the third quarter. Crossmark Global Holdings Inc. now owns 7,750 shares of the medical device company’s stock worth $554,000 after buying an additional 436 shares in the last quarter. KBC Group NV lifted its holdings in shares of Globus Medical by 0.5% during the third quarter. KBC Group NV now owns 45,505 shares of the medical device company’s stock valued at $3,255,000 after acquiring an additional 237 shares during the period. Quest Partners LLC bought a new position in shares of Globus Medical during the third quarter valued at $523,000. Pathstone Holdings LLC lifted its holdings in shares of Globus Medical by 2.6% during the third quarter. Pathstone Holdings LLC now owns 41,007 shares of the medical device company’s stock valued at $2,934,000 after acquiring an additional 1,055 shares during the period. Finally, Segall Bryant & Hamill LLC lifted its holdings in shares of Globus Medical by 7.2% during the third quarter. Segall Bryant & Hamill LLC now owns 387,737 shares of the medical device company’s stock valued at $27,739,000 after acquiring an additional 26,047 shares during the period. Institutional investors and hedge funds own 95.16% of the company’s stock.

Insider Buying and Selling at Globus Medical

In other Globus Medical news, CFO Keith W. Pfeil sold 14,167 shares of the stock in a transaction that occurred on Friday, January 10th. The stock was sold at an average price of $88.29, for a total transaction of $1,250,804.43. The sale was disclosed in a filing with the SEC, which is accessible through the SEC website. Corporate insiders own 18.54% of the company’s stock.

Globus Medical Company Profile

(Get Free Report)

Globus Medical, Inc, a medical device company, develops and commercializes healthcare solutions for patients with musculoskeletal disorders in the United States and internationally. The company offers spine products, such as traditional fusion implants comprising pedicle screw and rod systems, plating systems, intervertebral spacers, and corpectomy devices for treating degenerative and congenital conditions, deformity, tumors, and trauma injuries; treatment options for motion preservation technologies that consist of dynamic stabilization, total disc replacement, and interspinous distraction devices; interventional solutions to treat vertebral compression fractures; and regenerative biologic products comprising of allografts and synthetic alternatives.

Further Reading